P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
暂无分享,去创建一个
S. Ho | C. Kao | J. J. Wang | S. Tsai | T. J. Liu | Y. Ho | S. Changlai
[1] E. Franssen,et al. Visualization of multidrug resistance in vivo , 1999, European Journal of Nuclear Medicine.
[2] J. Kouyoumdjian,et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] L. Goldstein,et al. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] L. Kostakoglu,et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] R. Thomas,et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Mottolese,et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] A Ciarmiello,et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] J. Foekens,et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. , 1997, British Journal of Cancer.
[9] L. Kostakoglu,et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] G. Dekan,et al. MRP and MDR1 gene expression in primary breast carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. Kouyoumdjian,et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] G. Giaccone,et al. Prognostic relevance of P-glycoprotein expression in breast cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Kramer,et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.
[14] I. Ellis,et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.
[15] N. Lemoine,et al. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables , 1987, The Journal of pathology.
[16] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.
[17] K. Kohno,et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. , 1998, Oncology research.